Epidiolex Advisory Committee Appears To Be Covering US FDA's Bases, But Liver Injury Concerns Persist

Panel for first-ever marijuana derivative will discuss safety issues, including link to transaminase elevations, but low potential for abuse and strong efficacy suggest a smooth route to approval.

Airliner in flight
It looks like clear skies for GW Pharmaceuticals's childhood epilepsy drug Epidiolex (cannabidiol).

It seems as if the US FDA's calling of an advisory committee to vote on the risk/benefit profile of GW Pharmaceuticals PLC's childhood epilepsy drug Epidiolex (cannabidiol) is largely designed to cover the agency's bases, in that there is no agency-approved drug containing the marijuana derivative.

But the Peripheral and Central Nervous System Drugs Advisory Committee will also be weighing in on a number of safety...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers